News & analysis, rated.
Breaking AI developments, in-depth guides, real-world case studies, and analysis — each one rated so you know what matters.
Law Firms Now Train Custom AI Models on Their Own Workflows
Harvey, Kirkland & Ellis, and Thomson Reuters are fine-tuning open source LLMs on firm-specific data to automate complex legal work. Here's why the old strategy is back.
Perplexity Enters Legal Market With Hallucination-First Pitch
Perplexity is hosting 'Computer for Counsel' in New York next week to announce legal connectors and premium sources. Five Big Tech players now compete in legal AI, reshaping a traditionally insular market.
Crosby Law Firm Builds AI Practice on Fixed Fees and Lawyer Judgment
Crosby co-founder Ryan Daniels explains how an MSO model aligns incentives to deploy AI agents alongside experienced lawyers—and why the firm sometimes accepts losses to prove the model works.
Insilico's AI-Designed Drug Reaches First Human Trial
Insilico Medicine dosed the first patient with ISM8969, an NLRP3 inhibitor designed using AI. The Phase I study marks a clinical validation of AI-driven drug discovery in a real patient.
Abarca Health and LucyRx merge to build PBM for commercial and government
Abarca Health and LucyRx announced a strategic combination to create a pharmacy benefit manager serving both commercial and government markets. Details on deal terms and timing remain undisclosed.
$65B pharma M&A quarter signals patent cliff panic
US pharma deal value hit $65 billion in Q1 2026, the strongest quarter since 2020, as companies race to fill pipelines ahead of massive patent expirations. Here's what's driving the surge.
Turbine's Virtual Lab finds hidden cancer targets DepMap misses
Turbine screened 30,000 perturbation combinations to identify eight biomarker candidates for PARP inhibitor resistance. Two are now in clinical trials—including one unknown to DepMap alone.
LG AI and D&D Pharmatech team on oral peptide drugs via AI design
LG AI Research and D&D Pharmatech signed a partnership to develop tablet-form peptide treatments using AI to improve absorption and safety. The deal pairs LG's AI discovery models with D&D's formulation expertise.
Jazz Pharma, AbCellera Partner on T-Cell Cancer Antibodies for $56M
Jazz Pharmaceuticals and AbCellera signed a research deal worth up to $56 million upfront to develop T-cell engaging antibodies targeting solid tumors. Here's what the partnership covers.
Eli Lilly's retatrutide cuts weight 28% in Phase III, rivals bariatric surgery
At ADA 2026, retatrutide hit 28.3% mean weight loss at 12mg dose in 2,339 patients. Over 25% achieved ≥35% reduction. FDA submission expected late 2026.
NorthX and enGenes Link Bacterial Protein Production to Cut Scale-Up Delays
Two bioprocessing firms integrate E. coli strain design with GMP manufacturing to eliminate handovers between developers and manufacturers. Here's what that means for biosimilar and peptide timelines.
U.K. Lab Builds Continuous Gene Therapy Platform Matching Batch Output
The CGT Catapult's new continuous bioprocess for gene therapies matches or beats batch methods on yield and productivity. Here's what manufacturers need to know about a credible alternative.